

## Speaker



### APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?



**Zoe Garrett, MPhil, MRes**  
National Institute for Health and Care Excellence (NICE) & EUnetHTA  
Manchester, UK

## Building a model of sustainable HTA cooperation

Zoe Garrett  
Senior Technical Adviser, NICE  
Lead EUnetHTA JA3 WP7 National Implementation and Impact  
ISPOR Plenary: November 7, Glasgow



European network for Health Technology Assessment | JA3 2016 - 2020 | [www.eunetha.eu](http://www.eunetha.eu)




## EUnetHTA Joint Action 3 (2016-2020)

- European Network for Health Technology Assessment
- Aims to contribute to the development of a sustainable model of Health Technology Assessment (HTA) in Europe in collaboration with stakeholders and the European Commission
- Specific objectives:
  - To increase production of high quality joint HTA work
  - To increase uptake and implementation of joint HTA work
  - To support evidence-based, sustainable and equitable choices in healthcare and health technologies




European network for Health Technology Assessment | JA3 2016 – 2020 | [www.eunetha.eu](http://www.eunetha.eu)

## Whose model?



European network for Health Technology Assessment | JA3 2016 – 2020 | [www.eunetha.eu](http://www.eunetha.eu)

## Whose model?



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Status of health technology assessment

- HTA not established in all countries for all technologies
- Countries with HTA-related activity rather than a formal HTA system
- Agencies produce assessments themselves or evaluate evidence provided by the Industry



Yellow – data for pharma and non-pharma; Blue – data for pharma only; Red – No HTA process (in development)




European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Model characteristics

Model characteristic	Benefits
<ul style="list-style-type: none"> <li>• Explicitly supports agencies to develop their HTA systems and capability to use and produce HTA</li> <li>• Flexible implementation of joint HTA while systems establish and change</li> </ul>	<p>Agencies embed use of joint HTA into their processes as they establish and change</p> <p>Agencies become more familiar and efficient in using joint HTA and as experience grows more meaningful usage occurs</p>


## Predictability

- Agencies often react to requests:
  - HTA agencies not always involved in topic selection
  - Small number of agencies currently using horizon scanning
  - Little advanced notice of assessments being required
- Even when topics are known in advance, topics and data may be confidential limiting sharing



## Capacity

- Limited capacity to carry out assessments



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Model characteristics

Model characteristic	Benefits
<ul style="list-style-type: none"> <li>• Predictable, agencies know what to expect:                             <ul style="list-style-type: none"> <li>• Explicit topic selection and prioritisation criteria</li> <li>• Transparent topic selection and prioritisation processes</li> <li>• Advanced notification of topics for joint assessment</li> <li>• Annual work plans</li> </ul> </li> <li>• Forward-looking to identify possible priorities in advance:                             <ul style="list-style-type: none"> <li>• Collaborative horizon scanning</li> <li>• Early dialogues</li> </ul> </li> <li>• Involvement of decision makers and users in topic selection as well as HTA agencies</li> </ul>	<p>Topics chosen are relevant to the largest possible number of countries</p> <p>Joint HTA is seen as reliable and predictable source of HTA</p> <p>Agencies can plan to use joint HTA</p>




European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu


## Timeliness

- Variations in launch
- Different initiation times
- Inflexible and short timeframes
- HTA agency not the initiator


Can process start before marketing authorisation? (pharmaceuticals)



Time for assessment or evaluation (pharma % of countries (days))



Time for assessment or evaluation (non-pharma % of countries (days))



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Model characteristics



Model Characteristic	Benefit
<ul style="list-style-type: none"> <li>• Explicit consideration of timeliness of the assessment as part of topic scheduling</li> <li>• Coordinate with Industry to identify launch plans across Europe</li> <li>• In the short term, joint assessment is made available at the latest at marketing authorisation</li> </ul>	<p>Joint HTA is available when agencies and decision makers need it</p>



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Relevance

- Inconsistency caused by the relative effectiveness assessment and cost effectiveness information coming from different sources
- Variation in the range of domains needed in the assessment
- Requests for the assessment of a subgroup only



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Model characteristics

Model Characteristic	Benefit
<ul style="list-style-type: none"> <li>• Include project planning and scoping as part of topic selection</li> <li>• Support agencies to be involved in early project planning</li> <li>• Include users and decision makers in discussions about the information needed ranging from relative effectiveness assessment to full HTA</li> <li>• Work with Industry to ensure consistency of joint HTA with national in cost effectiveness analysis</li> </ul>	<p>Project plan and scope reflects a European scenario</p> <p>Industry can start to plan evidence requirements earlier to meet needs of joint HTA</p>



European network for Health Technology Assessment | JA3 2016 – 2020 | www.eunetha.eu

## Accountability and Transparency

- HTA is often part of a larger formal process requiring procedural transparency, accountability and availability of documents

Health Technology Assessment

Decision-making



## Model characteristics

Model Characteristic	Benefit
<ul style="list-style-type: none"><li>• Publish documents underpinning the assessment</li><li>• Transparency of the topic selection, prioritisation and assessment processes</li><li>• Transparency of conflicts of interest for authors and contributors</li></ul>	Joint HTA becomes a meaningful alternative to national HTA





## Conclusion

- A sustainable model of HTA cooperation provides an opportunity to make better use of HTA resources and to support evidence-based, sustainable and equitable choices in healthcare
- However, a sustainable model of HTA cooperation should also strive to be a solution to the challenges many agencies face
- To be sustainable, the model needs to:
  - Listen to a variety of stakeholder voices
  - Support agencies to develop and establish processes where needed
  - Be predictable and forward-looking
  - Produce timely and relevant outputs
  - Meet the requirements for accountability and transparency that go hand-in-hand with the context in which HTA is used



European network for Health Technology Assessment | JA3 2016 – 2020 | [www.eunetha.eu](http://www.eunetha.eu)

# Thank you

This presentation arises from the EUnetHTA Joint Action 3 which has received funding from the European Union, in the framework of the Health Programme



European network for Health Technology Assessment | JA3 2016 – 2020 | [www.eunetha.eu](http://www.eunetha.eu)